AstraZeneca's Camizestrant shows promising results in Phase 3 breast cancer trial

From Nasdaq: 2025-02-26 02:25:06

AstraZeneca plc announced positive results from the SERENA-6 Phase III trial of Camizestrant, showing statistically significant improvement in progression-free survival when combined with a CDK 4/6 inhibitor for advanced breast cancer patients with ESR1 mutations. Key secondary endpoints like time to second disease progression and overall survival are still being assessed. This trial is the first to use ctDNA-guided methodology for endocrine resistance. The safety profile of the combination treatment was consistent with established profiles of individual medications. Data will be presented at a medical meeting and shared with regulatory authorities.



Read more at Nasdaq: AstraZeneca’s Camizestrant Shows Positive Interim Results In SERENA-6 Phase 3 Trial